OCA: Sales acceleration, cost reduction, and lower gearing drive improved financial performance

About this update from Oceania Healthcare Ltd.

Underlying EBITDA rose 2.6% year-over-year, with strong cash inflow and reduced gearing to 37.5%. Focus is on accelerating sales, reducing unsold stock, and achieving NZD 5–7 million in cost savings for FY2026, while dividend resumption depends on sales and gearing.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Oceania Healthcare Ltd.